|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rensselaer Polytechnic Institute, Department of Chemistry and Chemical Biology, Troy, New York 12180, USA
Reprint requests to: Wilfredo Colón, Rensselaer Polytechnic Institute, Department of Chemistry and Chemical Biology, 110 8th Street, Troy, NY 12180, USA; e-mail: colonw{at}rpi.edu; fax: (518) 276-4887.
(RECEIVED January 31, 2005; FINAL REVISION April 14, 2005; ACCEPTED April 17, 2005)
| Abstract |
|---|
|
|
|---|
-helical structure. However, limited trypsin proteolysis experiments in urea showed a conserved digestion profile, suggesting the preservation of major backbone topological features in the urea-denatured state of SAA2.2. The marginal stability of hexameric SAA2.2 and the presence of residual structure in the denatured monomeric protein suggest that both forms may interconvert in vivo to exert different functions to meet the various needs during normal physiological conditions and in response to inflammatory stimuli. Keywords: amyloidosis; HDL; inflammation; acute phase; amyloid fibril
Abbreviations: SAA, serum amyloid A MOPS, 3-(N-morpholino) propanesulfonic acid Tris, 2-amino-2-hydroxymethyl-1,3-propanediol GCL, Glutaraldehyde cross-linking SEC, size exclusion chromatography CD, circular dichroism RT, room temperature
max, wavelength of maximum fluorescence emission MRE or
, molar residue ellipticity
Article published online ahead of print. Article and publication date are at http://www.proteinscience.org/cgi/doi/10.1110/ps.051387005.
| Introduction |
|---|
|
|
|---|
Although SAA appears to have very important functions in vivo, these remain largely obscure, because the high tendency of HDL-free SAA to aggregate in vitro has limited experimental work, including the solution of its three-dimensional structure. Recently, we found that murine SAA2.2, a nonamyloidogenic isoform in vivo, has modest solubility and forms a hexameric structure with a putative central channel (Wang et al. 2002). To investigate the stability of SAA2.2, we used various biochemical and biophysical techniques to monitor its structural changes upon urea-induced denaturation. Here we show that hexameric SAA2.2 is marginally stable and undergoes a concerted loss of quaternary, tertiary, and secondary structure. These results have implications concerning the in vivo amyloidogenicity and the multiple functions of SAA.
| Results |
|---|
|
|
|---|
-amino group (Craig 1988). When SAA2.2 was incubated in different concentrations of urea, GCL clearly showed a hexamer to monomer transition without population of dimeric or trimeric intermediates (Fig. 1
|
|
max) from ~340 nm (without urea) to ~354 nm (at 5.3 M urea) (Fig. 3B
max in the 02 M urea range, suggesting that the hexamer dissociated to a monomeric structure with one or more Trp residues partially protected from the solvent.
|
-helical structure
-helical and ~10%
-sheet structure (Wang et al. 2002), the CD signal is mainly monitoring the presence of
-helical structure. The CD spectra recorded at various urea concentrations show a dramatic loss of
-helical content at low urea concentrations (Fig. 4A
|
|
| Discussion |
|---|
|
|
|---|
|
Hexameric SAA2.2 is marginally stable
The changes in quaternary (Figs. 1
3![]()
) and secondary (Fig. 4
) structures of SAA2.2 at urea concentrations as low as 0.1 M clearly show that hexameric SAA2.2 is a marginally stable protein. Due to the lack of a pretransition baseline, it was not possible to fit the data to obtain a reliable free-energy change of unfolding. Nevertheless, the clear qualitative observation of a broad denaturation transition (i.e., low m-value) that ranges from 0 to 23 M urea, combined with the low-denaturation mid-point (cm), indicate that hexameric SAA2.2 has marginal stability. Often, the very low in vitro stability exhibited by some proteins is due to the absence of ligands or cofactors, which play a stabilizing role. In addition to its ability to bind HDL, it has been shown or proposed that SAA may bind a number of ligands in vivo, including calcium (Turnell et al. 1986), integrin and fibronectin-like binding elements (Preciado-Patt et al. 1994), and heparin/heparan sulfate (Ancsin and Kisilevsky 1999a). Thus, it is possible that hexameric SAA2.2 may be stabilized in vivo by binding to these or other ligands. It is also worth noting that during inflammation, the SAA concentration may increase (up to 1000-fold) to above 1 mg/mL, which is 1020 times higher than the concentrations used in this study. Such high SAA concentration could significantly stabilize the hexamer.
The marginal stability of SAA2.2 shown here is in agreement with our observation that even at physiological temperature (37°C), SAA2.2 dissociates into a monomer and loses most of its secondary structure (Wang et al. 2005). As shown in the present study, the temperature-induced denaturation of SAA2.2 involved a hexamer to monomer transition without significant population of intermediates, and even though most of the secondary structure of SAA2.2 was lost at 37°C, limited proteolysis experiments also showed that the denatured monomer retained some of the topological features of the hexamer. Therefore, it seems that at 37°C, monomeric SAA has structural properties similar to "natively unfolded" proteins, a class of proteins that are mainly characterized by lacking well-defined structure in vitro (Wright and Dyson 1999; Uversky 2002). Thus, unless the hexameric protein is stabilized in vivo by ligand binding or by the dramatic increase in its concentration as a result of inflammation, SAA may exist as a monomeric natively unfolded protein. This may explain in part SAAs ability to bind many ligands, as it is becoming accepted that the natively unfolded structure of many proteins may be required for molecular recognition functions, such as oligomerization and binding to many partners (Dafforn and Smith 2004).
Implications for SAA function and amyloid fibril formation in vivo
The marginal stability of SAA is likely to have in vivo functional consequences. For example, the hexameric and monomeric forms of SAA may bind to different ligands, as suggested by the observation that monomeric, but not hexameric, SAA2.2 binds to HDL in vitro (Wang and Colón 2004). Therefore, the marginal stability of SAA may modulate its functions by allowing easy conversion between different oligomeric forms. In this context, the increase in SAA concentration during inflammation may stabilize the hexamer, and thereby serve as a regulatory mechanism to activate host defense functions required during an acute phase response. In addition, the ability of monomeric SAA2.2 to retain some of the hexamer topological features when denatured under mild denaturing conditions (2 M urea or 37°C) in vitro suggests that it may have other in vivo functions aside from HDL binding. This would help explain the large number of functions related to cholesterol metabolism and innate immunity that have been attributed to SAA (Uhlar and Whitehead 1999).
The marginal stability of SAA2.2 may also have a profound impact on the ability of amyloidogenic SAA isoforms to deposit into amyloid fibrils in vivo, leading to AA amyloidosis. Preliminary data have shown that the murine SAA1.1 isoform, which is amyloidogenic in vivo, is also a very unstable protein (L. Wang and W. Colón, unpubl.). The very high (97/103) sequence identity between the SAA2.2 and the amyloidogenic SAA1.1 isoforms, together with our observation that SAA2.2 can easily form amyloid fibrils in vitro at 37°C (Wang et al. 2005), suggest that although SAA2.2 is nonamyloidogenic in vivo, it still possess some of the intrinsic amyloidogenicity of SAA1.1. Thus, SAA2.2 may be a good model for understanding the mechanism of amyloid formation by SAA1.1. Since the formation of SAA amyloid fibrils involves the misfolding into a
-rich amyloidogenic species, the marginal stability of SAA is expected to facilitate its misfolding. This is consistent with the observation that at 37°C, SAA2.2 dissociates in vitro and misfolds into a
-rich monomeric species that self-assembles into amyloid fibrils (Wang et al. 2005). Although the marginal stability of SAA may increase its susceptibility to amyloid formation, it may also provide a means for allowing the rapid turnover of the protein. This may be especially important in the case of SAA, since its concentration can increase up to 1000 times in 24 h upon an inflammatory insult (McAdam and Sipe 1976). Since the occurrence of AA amyloidosis is relatively rare among patients suffering from chronic inflammatory diseases, it appears that other in vivo factors, such as ligand binding and an efficient quality control system, play an important role in keeping this marginally stable protein from frequently depositing into amyloid fibrils. In similar fashion, a compromised quality control system and the abnormal interaction of SAA with ligands or membranes may enhance its ability to deposit into amyloid fibrils (Ancsin and Kisilevsky 1999b). Thus, a better understanding of the mechanism of SAA amyloid formation in vivo and the role of SAA in other pathological processes (Urieli-Shoval et al. 2000) will require elucidating the relationship amongst its structure, stability, and ligand binding, and understanding how these are modulated in vivo.
| Materials and methods |
|---|
|
|
|---|
Glutaraldehyde cross-linking
SAA2.2 samples (50 µg/mL in MOPS buffer [pH 7.4], in the absence or the presence of urea) were preincubated at 20°C for 10 min, and then cross-linked with 0.7% (v/v) glutaraldehyde for 20 min as previously described (Wang et al. 2002). The crosslinking reaction was quenched by the addition of Tris and the extent of cross-linking was analyzed by SDS-PAGE. The gel was digitally photographed and quantitatively analyzed using the AlphaEaseFC software (Alpha Innotech Corp.).
Reverse phase and size-exclusion chromatography
A Gold Noveau Beckman Coulter HPLC instrument was used with a single wavelength absorbance detector (set at 220 nm). For analysis of limited trypsin digestion products, an analytic 4.6 mmx25 cm C4 reverse phase column (Vydac) was used at a flow rate of 0.66 mL/min. A 5%90% linear gradient of aqueous solution (0.1% [v/v] trifluoroacetic acid and 90% [v/v] acetonitrile) was applied over 85 min, and the column was regenerated with 0.1% trifluoroacetic acid.
To monitor the urea-induced quaternary structural change, SAA2.2 samples (20 µL of 0.1 mg/mL, without or with urea) were incubated at room temperature for 10 min, and then analyzed by size exclusion chromatography on a Superdex 75 PC 3.2/30 column (Amersham Pharmacia Biotech) at a flow rate of 0.1 mL/min. The elution buffer (20 mM Tris buffer with 0.4 M NaCl) was the same as the sample buffer, including the same concentration of urea.
Fluorescence polarization spectroscopy
When a fluorescent molecule is excited by plane-polarized light, it will emit plane-polarized light if the molecule remains stationary between the time of excitation and emission (Lakowicz 1999). Therefore, the degree of polarization depends on the molecules rotational correlation time. The faster the molecule rotates and tumbles, i.e., the shorter the rotational correlation time, the smaller the polarization value will be. Since the rotational correlation time is based on the size and volume of the protein, fluorescence polarization can be used to study the quaternary structure changes in protein denaturation studies (Checovich et al. 1995). The polarization value is calculated as (I00-00G*I00-90)/ (I00-00+G*I00-90), while G=I90-00/I90-90. The first two digits in the fluorescence intensity (I) subscript represent the rotation in degrees (0° or 90°) of the polarizer lens in the excitation side, while the last two digits are for the polarizer on the emission side. The factor G accounts for the transmission difference of the two polarizers.
A Hitachi F-4500 fluorescence spectrophotometer was used with excitation wavelength at 295 nm and a slit width of 5 nm. Excitation at 295 nm was used to avoid exciting the six Tyr residues present in SAA2.2. The emission slit width was set at 10 nm. A polarizer lens was installed at the excitation as well as the emission side and arranged at either 0° or 90° rotation from each other. Two stock samples (50 µg/mL SAA2.2 in MOPS buffer) were made with no urea or containing 9 M urea. Individual samples were prepared by a codilution method, in which SAA2.2 samples of progressively higher urea concentrations were made by repetitive withdrawal from a SAA2.2 sample (originally in 0 M urea) in the cell, followed by addition of the same volume of the SAA2.2 stock sample in 9 M urea. At each urea concentration, the sample was incubated for 10 min at 20°C before the 20-sec time scan. The signal did not change with longer incubation time, indicating that equilibrium had been reached. The codilution method described here for making protein samples containing different concentrations of urea is only appropriate with proteins that denature reversibly. We have previously shown that hexameric SAA2.2 can be reversibly denatured after incubation in 6 M urea (Wang et al. 2002). This is consistent with our purification protocol, which is carried out under denaturing conditions.
Circular dichroism
Spectra were recorded on an OLIS CD instrument with a 0.1-cm pathway sample cuvette. The SAA2.2 samples with different concentrations of urea were made by the codilution method described above. Each sample was incubated at 20°C for 20 min before three wavelength scans were collected, with a wavelength increment of 0.5 nm and a time table of 2 sec (260230 nm) and 8 sec (230200 nm). Additionally, 2-min time scans at 222 and 250 nm were also recorded to generate reliable transition curves. The signal at 250 nm was used as an internal control to correct for small fluctuations in the baseline.
Limited proteolysis
SAA2.2 sample (60 µL of 0.1 mg/mL without or with a certain concentration of urea) was preincubated at 20°C for 30 min and then partially digested by TPCK-treated trypsin (Sigma) with an SAA:trypsin ratio of 120:1. To balance the lower trypsin activity in higher urea concentration, proteolysis time was adjusted to obtain a similar degree of full-length SAA2.2 degradation. The proteolysis reaction was stopped by adding 0.1% (v/v) trifluoroacetic acid and then analyzed by analytic C4 reverse-phase HPLC as described above.
| Footnotes |
|---|
| Acknowledgments |
|---|
| References |
|---|
|
|
|---|
. 1999b. Laminin interactions with the apoproteins of acute-phase HDL: Preliminary mapping of the laminin binding site on serum amyloid A. Amyloid 6: 3747.[Medline]
Benditt, E.P. and Eriksen, N. 1977. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc. Natl. Acad. Sci. 74: 40254028.
Checovich, W.J., Bolger, R.E., and Burke, T. 1995. Fluorescence polarization A new tool for cell and molecular biology. Nature 375: 254256.[CrossRef][Medline]
Colón, W. 1999. Analysis of protein structure by solution optical spectroscopy. Methods Enzymol. 309: 605632.[Medline]
Craig, W.S. 1988. Determination of quaternary structure of an active enzyme using chemical cross-linking with glutaraldehyde. Methods Enzymol. 156: 333345.[Medline]
Dafforn, T.R. and Smith, C.J. 2004. Natively unfolded domains in endocytosis: Hooks, lines and linkers. EMBO Rep. 5: 10461052.[CrossRef][Medline]
Delanghe, J.R., Langlois, M.R., de Bacquer, D., Mak, R., Capel, P., van Tenterghem, L., and de Backer, G. 2002. Discriminative value of serum amyloid A and other acute-phase proteins for coronary heart disease. Atherosclerosis 160: 471476.[CrossRef][Medline]
Eftink, M.R. 1994. The use of fluorescence methods to monitor unfolding transitions in proteins. Biophys. J. 66: 482501.[Medline]
Gillmore, J.D., Lovat, L.B., Persey, M.R., Pepys, M.B., and Hawkins, P.N. 2001. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358: 2429.[CrossRef][Medline]
Husebekk, A., Skogen, B., Husby, G., and Marhaug, G. 1985. Transformation of amyloid precursor SAA to protein AA and incorporation in amyloid fibrils in vivo. Scand. J. Immunol. 21: 283287.[CrossRef][Medline]
Lakowicz, J.R. 1999. Principles of fluorescence spectroscopy, 2d ed. Kluwer Academic/Plenum Publishers, New York.
Liang, J.S., Schreiber, B.M., Salmona, M., Phillip, G., Gonnerman, W.A., de Beer, F.C., and Sipe, J.D. 1996. Amino terminal region of acute phase, but not constitutive, serum amyloid A (apoSAA) specifically binds and transports cholesterol into aortic smooth muscle and HepG2 cells. J. Lipid Res. 37: 21092116.[Abstract]
Liang, J., Elliott-Bryant, R., Hajri, T., Sipe, J.D., and Cathcart, E.S. 1998. A unique amyloidogenic apolipoprotein serum amyloid A (apoSAA) isoform expressed by the amyloid resistant CE/J mouse strain exhibits higher affinity for macrophages than apoSAA1 and apoSAA2 expressed by amyloid susceptible CBA/J mice. Biochim. Biophys. Acta 1394: 121126.[Medline]
Libby, P., Ridker, P.M., and Maseri, A. 2002. Inflammation and atherosclerosis. Circulation 105: 11351143.
McAdam, K.P.W.J. and Sipe, J.D. 1976. Murine model for human secondary amyloidosis: Genetic variability of the acute-phase serum protein SAA response to endotoxins and casein. J. Exp. Med. 144: 11211127.
Patel, H., Bramall, J., Warters, H., De Beers, M.C., and Woo, P. 1996. Expression of recombinant human serum amyloid A in mammalian cells and demonstration of the region necessary for high-density lipoprotein binding and amyloid fibril formation by site-directed mutagenesis. Biochem. J. 318: 10411049.
Preciado-Patt, L., Levartowsky, D., Prass, M., Hershkoviz, R., Lider, O., and Fridkin, M. 1994. Inhibition of cell adhesion to glycoproteins of the extracellular matrix by peptides corresponding to serum amyloid A. Toward understanding the physiological role of an enigmatic protein. Eur. J. Biochem. 223: 3542.[Medline]
Saadeddin, S.M., Habbab, M.A., and Ferns, G.A. 2002. Markers of inflammation and coronary artery disease. Med. Sci. Monit. 8: RA5RA12.[Medline]
Turnell, W., Sarra, R., Glover, I.D., Baum, J.O., Caspi, D., Baltz, M.L., and Pepys, M.B. 1986. Secondary structure prediction of human SAA1. Presumptive identification of calcium and lipid binding sites. Mol. Biol. Med. 3: 387407.[Medline]
Uhlar, C.M. and Whitehead, A.S. 1999. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem. 265: 501523.[Medline]
Uhlar, C.M., Burgess, C.J., Sharp, P.M., and Whitehead, A.S. 1994. Evolution of the serum amyloid A (SAA) protein superfamily. Genomics 19: 228235.[CrossRef][Medline]
Urieli-Shoval, S., Linke, R.P., and Matzner, Y. 2000. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr. Opin. Hematol. 7: 6469.[CrossRef][Medline]
Uversky, V.N. 2002. Natively unfolded proteins: A point where biology waits for physics. Protein Sci. 11: 739756.
Wang, L. and Colón, W. 2004. The interaction between apolipoprotein serum amyloid A and high-density lipoprotein. Biochem. Biophys. Res. Commun. 317: 157161.[CrossRef][Medline]
Wang, L., Lashuel, H.A., Walz, T., and Colón, W. 2002. Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel. Proc. Natl. Acad. Sci. 99: 1594715952.
Wang, L., Lashuel, H.A., and Colón, W. 2005. From hexamer to amyloid: Marginal stability of apolipoprotein SAA2.2 leads to in vitro fibril formation at physiological temperature. Amyloid: J. Protein Fold. Disorders 12: (in press).
Wright, P.E. and Dyson, H.J. 1999. Intrinsically unstructured proteins: Reassessing the protein structure-function paradigm. J. Mol. Biol. 293: 321331.[CrossRef][Medline]
Yamada, T., Kluve-Beckerman, B., Liepnieks, J.J., and Benson, M.D. 1994. Fibril formation from recombinant human serum amyloid A. Biochim. Biophys. Acta 1226: 323329.[Medline]
![]()
CiteULike
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |